PCA
CRL icon

Providence Capital Advisors’s Charles River Laboratories CRL Stock Holding History

Providence Capital Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5
Closed -$1K – 322
2022
Q1 		$1K Buy
+5
New +$1.54K ﹤0.01% 415

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Providence Capital Advisors's CRL Position: Q2 2022 in Review

Providence Capital Advisors sold out of Charles River Laboratories (CRL) in Q2 2022, closing a stake of 5 shares — an estimated $1K sold.

Providence Capital Advisors first reported a position in CRL in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 627 funds tracked by Wall St. Rank hold CRL as of Q2 2022.

  • Providence Capital Advisors reported no remaining Charles River Laboratories position as of Q2 2022 after selling out during the quarter.
  • Providence Capital Advisors sold 5 Charles River Laboratories shares in Q2 2022, an estimated $1K.
  • Providence Capital Advisors first reported a position in Charles River Laboratories in Q1 2022 and held it in 1 quarter.
  • Providence Capital Advisors's Charles River Laboratories position peaked at $1K in Q1 2022.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2022.

Based on Providence Capital Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.